Steven Grant

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9313546/publications.pdf

Version: 2024-02-01

162 papers	17,132 citations	23567 58 h-index	14208 128 g-index
167 all docs	167 docs citations	167 times ranked	25733 citing authors

#	Article	IF	Citations
1	Chk1 Inhibition Potently Blocks STAT3 Tyrosine705 Phosphorylation, DNA-Binding Activity, and Activation of Downstream Targets in Human Multiple Myeloma Cells. Molecular Cancer Research, 2022, 20, 456-467.	3.4	3
2	Mechanisms underlying synergism between circularized tumor necrosis factorâ€related apoptosis inducing ligand and bortezomib in bortezomibâ€sensitive or â€resistant myeloma cells. Hematological Oncology, 2022, 40, 999-1008.	1.7	4
3	Targeting cereblon in AML. Blood, 2021, 137, 584-586.	1.4	2
4	IAP and HDAC inhibitors interact synergistically in myeloma cells through noncanonical NF-ÎºBâ€“ and caspase-8â€“dependent mechanisms. Blood Advances, 2021, 5, 3776-3788.	5.2	10
5	Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome. Leukemia and Lymphoma, 2021, 62, 1187-1194.	1.3	6
6	Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models. Haematologica, 2020, 105, 697-707.	3.5	78
7	Enhancing venetoclax activity in hematological malignancies. Expert Opinion on Investigational Drugs, 2020, 29, 697-708.	4.1	7
8	The Covalent CDK7 Inhibitor THZ1 Potently Induces Apoptosis in Multiple Myeloma Cells In Vitro and In Vivo. Clinical Cancer Research, 2019, 25, 6195-6205.	7.0	35
9	The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo. Journal of Hematology and Oncology, 2019, 12, 25.	17.0	19
10	NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263. Clinical Cancer Research, 2019, 25, 312-324.	7.0	11
11	Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells. Cancer Research, 2018, 78, 3075-3086.	0.9	91
12	R-spondin(g) to syndecan-1 in myeloma. Blood, 2018, 131, 946-947.	1.4	1
13	Rational combination strategies to enhance venetoclax activity and overcome resistance in hematologic malignancies. Leukemia and Lymphoma, 2018, 59, 1292-1299.	1.3	8
14	Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo. British Journal of Cancer, 2018, 118, 388-397.	6.4	23
15	Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms. BMC Cancer, 2018, 18, 1129.	2.6	19
16	A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 569-575.e1.	0.4	30
17	Experimental design and statistical analysis for three-drug combination studies. Statistical Methods in Medical Research, 2017, 26, 1261-1280.	1.5	21
18	Nonlinear response surface in the study of interaction analysis of three combination drugs. Biometrical Journal, 2017, 59, 9-24.	1.0	2

#	Article	IF	Citations
19	Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms. Oncotarget, 2017, 8, 31478-31493.	1.8	16
20	Positive transcription elongation factor b (P-TEFb) is a therapeutic target in human multiple myeloma. Oncotarget, 2017, 8, 59476-59491.	1.8	21
21	A Mitochondrial-targeted purine-based HSP90 antagonist for leukemia therapy. Oncotarget, 2017, 8, 112184-112198.	1.8	17
22	The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR. Blood, 2016, 127, 2219-2230.	1.4	42
23	Atg7 in AML: a double-edged sword?. Blood, 2016, 128, 1163-1165.	1.4	4
24	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
25	Update on rational targeted therapy in AML. Blood Reviews, 2016, 30, 275-283.	5.7	67
26	Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas. Leukemia and Lymphoma, 2016, 57, 635-643.	1.3	21
27	A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma. Clinical Cancer Research, 2016, 22, 1067-1075.	7.0	35
28	Rational Combinations of Targeted Agents in AML. Journal of Clinical Medicine, 2015, 4, 634-664.	2.4	22
29	Romidepsin for the treatment of non-Hodgkinâ€™s lymphoma. Expert Opinion on Investigational Drugs, 2015, 24, 965-979.	4.1	17
30	Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation. Haematologica, 2015, 100, 1553-1563.	3.5	27
31	Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL+ leukemia cells. Leukemia Research, 2015, 39, 65-71.	0.8	18
32	Dual targeting of the thioredoxin and glutathione antioxidant systems in malignant B cells: A novel synergistic therapeutic approach. Experimental Hematology, 2015, 43, 89-99.	0.4	44
33	Co-Administration of the mTORC1/TORC2 Inhibitor INK128 and the Bcl-2/Bcl-Xl Antagonist ABT-737 Kills Human Myeloid Leukemia Cells through Mcl-1 Down-Regulation and AKT Inactivation. Blood, 2015, 126, 3676-3676.	1.4	1
34	Bortezomib for the treatment of non-Hodgkinâ€™s lymphoma. Expert Opinion on Pharmacotherapy, 2014, 15, 2443-2459.	1.8	32
35	Pazopanib and HDAC inhibitors interact to kill sarcoma cells. Cancer Biology and Therapy, 2014, 15, 578-585.	3.4	42
36	In Vitro and In Vivo Interactions between the HDAC6 Inhibitor Ricolinostat (ACY1215) and the Irreversible Proteasome Inhibitor Carfilzomib in Non-Hodgkin Lymphoma Cells. Molecular Cancer Therapeutics, 2014, 13, 2886-2897.	4.1	37

#	Article	IF	Citations
37	PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells. Cancer Biology and Therapy, 2014, 15, 758-767.	3.4	48
38	HDAC inhibitors enhance the lethality of low dose salinomycin in parental and stem-like GBM cells. Cancer Biology and Therapy, 2014, 15, 305-316.	3.4	32
39	Dinaciclib (SCH727965) Inhibits the Unfolded Protein Response through a CDK1- and 5-Dependent Mechanism. Molecular Cancer Therapeutics, 2014, 13, 662-674.	4.1	39
40	A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis. Blood, 2014, 124, 2687-2697.	1.4	82
41	Phase I Trial of Bortezomib (PS-341; NSC 681239) and â€œNonhybridâ€•(Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms. Clinical Cancer Research, 2014, 20, 5652-5662.	7.0	26
42	Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights. , 2014, 143, 323-336.		219
43	Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML. Physiological Genomics, 2014, 46, 448-456.	2.3	26
44	Phosphodiesterase 5 Inhibitors Enhance Chemotherapy Killing in Gastrointestinal/Genitourinary Cancer Cells. Molecular Pharmacology, 2014, 85, 408-419.	2.3	69
45	Orphan drug designation for pracinostat, volasertib and alvocidib in AML. Leukemia Research, 2014, 38, 862-865.	0.8	26
46	Targeting SQSTM1/p62 Induces Cargo Loading Failure and Converts Autophagy to Apoptosis via NBK/Bik. Molecular and Cellular Biology, 2014, 34, 3435-3449.	2.3	63
47	Regulation of OSU-03012 Toxicity by ER Stress Proteins and ER Stressâ€“Inducing Drugs. Molecular Cancer Therapeutics, 2014, 13, 2384-2398.	4.1	42
48	Targeting Mantle Cell Lymphoma with a Strategy of Combined Proteasome and Histone Deacetylase Inhibition. Resistance To Targeted Anti-cancer Therapeutics, 2014, , 149-179.	0.1	2
49	Circumvention of Mcl-1-Dependent Drug Resistance by Simultaneous Chk1 and MEK1/2 Inhibition in Human Multiple Myeloma Cells. PLoS ONE, 2014, 9, e89064.	2.5	27
50	Inhibition of the MDM2 E3 Ligase Induces Apoptosis and Autophagy in Wild-Type and Mutant p53 Models of Multiple Myeloma, and Acts Synergistically with ABT-737. PLoS ONE, 2014, 9, e103015.	2.5	26
51	Mcl-1 as a therapeutic target in acute myelogenous leukemia (AML). Leukemia Research Reports, 2013, 2, 12-14.	0.4	55
52	Dual Inhibition of Bcl-2 and Bcl-xL Strikingly Enhances PI3K Inhibition-Induced Apoptosis in Human Myeloid Leukemia Cells through a GSK3- and Bim-Dependent Mechanism. Cancer Research, 2013, 73, 1340-1351.	0.9	139
53	Cyclin-dependent kinase inhibitor therapy for hematologic malignancies. Expert Opinion on Investigational Drugs, 2013, 22, 723-738.	4.1	132
54	The Novel Chk1 Inhibitor MK-8776 Sensitizes Human Leukemia Cells to HDAC Inhibitors by Targeting the Intra-S Checkpoint and DNA Replication and Repair. Molecular Cancer Therapeutics, 2013, 12, 878-889.	4.1	51

#	Article	IF	Citations
55	PLK1 Inhibitors Synergistically Potentiate HDAC Inhibitor Lethality in Imatinib Mesylateâ€“Sensitive or â€“Resistant BCR/ABL+ Leukemia Cells In Vitro and In Vivo. Clinical Cancer Research, 2013, 19, 404-414.	7.0	24
56	A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2. Clinical Cancer Research, 2013, 19, 1873-1883.	7.0	32
57	The Bruton tyrosine kinase (<scp>BTK</scp>) inhibitor <scp>PCI</scp>â€32765 synergistically increases proteasome inhibitor activity in diffuse largeâ€B cell lymphoma (<scp>DLBCL</scp>) and mantle cell lymphoma (<scp>MCL</scp>) cells sensitive or resistant to bortezomib. British Journal of Haematology, 2013, 161, 43-56.	2.5	81
58	Phase I Trial Of Carfilzomib In Combination With Vorinostat (SAHA) In Patients With Relapsed/Refractory B-Cell Lymphomas. Blood, 2013, 122, 4375-4375.	1.4	5
59	Biological Characterization of 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) as a Selective Sphingosine Kinase-2 Inhibitor and Anticancer Agent. PLoS ONE, 2013, 8, e56471.	2.5	67
60	Complementary combinations: what treatments will become key to the battle against acute myelogenous leukemia?. Expert Review of Hematology, 2012, 5, 475-478.	2.2	3
61	Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells In Vitro and In Vivo. Molecular Cancer Therapeutics, 2012, 11, 1122-1132.	4.1	29
62	Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process. Blood, 2012, 119, 6089-6098.	1.4	98
63	CDK Inhibitors Upregulate BH3-Only Proteins to Sensitize Human Myeloma Cells to BH3 Mimetic Therapies. Cancer Research, 2012, 72, 4225-4237.	0.9	51
64	Proteasome inhibitors in mantle cell lymphoma. Best Practice and Research in Clinical Haematology, 2012, 25, 133-141.	1.7	25
65	A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax^{Â®}). Epigenomics, 2012, 4, 571-589.	2.1	39
66	Histone Deacetylase Inhibitors and Rational Combination Therapies. Advances in Cancer Research, 2012, 116, 199-237.	5.0	39
67	Resveratrol Sensitizes Acute Myelogenous Leukemia Cells to Histone Deacetylase Inhibitors through Reactive Oxygen Species-Mediated Activation of the Extrinsic Apoptotic Pathway. Molecular Pharmacology, 2012, 82, 1030-1041.	2.3	36
68	Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies. Cancer Chemotherapy and Pharmacology, 2012, 69, 1657-1667.	2.3	18
69	LBH-589 (panobinostat) potentiates fludarabine anti-leukemic activity through a JNK- and XIAP-dependent mechanism. Leukemia Research, 2012, 36, 491-498.	0.8	12
70	FAM83A and FAM83B: candidate oncogenes and TKI resistance mediators. Journal of Clinical Investigation, 2012, 122, 3048-3051.	8.2	45
71	Disruption of Src function potentiates Chk1-inhibitorâ€“induced apoptosis in human multiple myeloma cells in vitro and in vivo. Blood, 2011, 117, 1947-1957.	1.4	29
72	Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2. Blood, 2011, 118, 5189-5200.	1.4	42

#	Article	IF	Citations
73	Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NFâ€ÎºB and Bim. British Journal of Haematology, 2011, 153, 222-235.	2.5	56
74	Targeting Waldenstrom macroglobulinemia with histone deacetylase inhibitors. Leukemia and Lymphoma, 2011, 52, 1623-1625.	1.3	5
75	HDAC Inhibitors Potentiate the Activity of the BCR/ABL Kinase Inhibitor KW-2449 in Imatinib-Sensitive or -Resistant BCR/ABL+ Leukemia Cells In Vitro and In Vivo. Clinical Cancer Research, 2011, 17, 3219-3232.	7.0	72
76	Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms. Clinical Cancer Research, 2011, 17, 3388-3397.	7.0	49
77	Disruption of ÎºB Kinase (IKK)-mediated RelA Serine 536 Phosphorylation Sensitizes Human Multiple Myeloma Cells to Histone Deacetylase (HDAC) Inhibitors. Journal of Biological Chemistry, 2011, 286, 34036-34050.	3.4	35
78	Combining proteasome with cell cycle inhibitors: a dual attack potentially applicable to multiple hematopoietic malignancies. Expert Review of Hematology, 2011, 4, 483-486.	2.2	4
79	Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells In Vitro and In Vivo. Molecular Cancer Therapeutics, 2011, 10, 1686-1697.	4.1	60
80	The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood, 2011, 117, 2807-2812.	1.4	186
81	The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood, 2010, 115, 4478-4487.	1.4	105
82	Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis. Leukemia Research, 2010, 34, 379-386.	0.8	26
83	The NF (Nuclear factor)â€ÎºB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1â€dependent apoptosis in human acute myeloid leukaemia cells. British Journal of Haematology, 2010, 151, 70-83.	2.5	62
84	Sorafenib Activates CD95 and Promotes Autophagy and Cell Death via Src Family Kinases in Gastrointestinal Tumor Cells. Molecular Cancer Therapeutics, 2010, 9, 2220-2231.	4.1	79
85	Vorinostat and Sorafenib Increase CD95 Activation in Gastrointestinal Tumor Cells through a Ca2+-De novo Ceramide-PP2A-Reactive Oxygen Speciesâ€“Dependent Signaling Pathway. Cancer Research, 2010, 70, 6313-6324.	0.9	95
86	Histone Deacetylase Inhibitors Activate NF-ÎºB in Human Leukemia Cells through an ATM/NEMO-related Pathway. Journal of Biological Chemistry, 2010, 285, 10064-10077.	3.4	57
87	Targeting Chk1 in the replicative stress response. Cell Cycle, 2010, 9, 1025-1030.	2.6	19
88	HDAC inhibitors repress the polycomb protein BMI1. Cell Cycle, 2010, 9, 2722-2730.	2.6	3
89	New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network. Clinical Cancer Research, 2010, 16, 376-383.	7.0	389
90	Bim Upregulation by Histone Deacetylase Inhibitors Mediates Interactions with the Bcl-2 Antagonist ABT-737: Evidence for Distinct Roles for Bcl-2, Bcl-x_L, and Mcl-1. Molecular and Cellular Biology, 2009, 29, 6149-6169.	2.3	123

#	Article	IF	Citations
91	Inhibition of MCL-1 enhances Lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy. Cancer Biology and Therapy, 2009, 8, 2084-2096.	3.4	88
92	Targeting Histone Demethylases in Cancer Therapy. Clinical Cancer Research, 2009, 15, 7111-7113.	7.0	30
93	Selectively killing transformed cells through proteasome inhibition. Cell Cycle, 2009, 8, 3073-3077.	2.6	1
94	BCL-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress. Cancer Biology and Therapy, 2009, 8, 808-819.	3.4	34
95	Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma. Clinical Cancer Research, 2009, 15, 5250-5257.	7.0	228
96	Synergistic combinations of signaling pathway inhibitors: Mechanisms for improved cancer therapy. Drug Resistance Updates, 2009, 12, 65-73.	14.4	45
97	New agents for AML and MDS. Best Practice and Research in Clinical Haematology, 2009, 22, 501-507.	1.7	6
98	The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways. Blood, 2009, 114, 4507-4516.	1.4	77
99	Targeting CDK9 Dramatically Potentiates ABT-737-Induced Apoptosis in Human Multiple Myeloma Cells through a Bim-Dependent Mechanism.. Blood, 2009, 114, 297-297.	1.4	3
100	Is the focus moving toward a combination of targeted drugs?. Best Practice and Research in Clinical Haematology, 2008, 21, 629-637.	1.7	21
101	Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions. Molecular Cancer Therapeutics, 2008, 7, 3285-3297.	4.1	104
102	Interactions between Bortezomib and Romidepsin and Belinostat in Chronic Lymphocytic Leukemia Cells. Clinical Cancer Research, 2008, 14, 549-558.	7.0	86
103	Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. Cancer Biology and Therapy, 2008, 7, 1648-1662.	3.4	159
104	Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate. Blood, 2008, 112, 793-804.	1.4	61
105	Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitorâ€“induced DNA damage in vitro and in vivo in human multiple myeloma cells. Blood, 2008, 112, 2439-2449.	1.4	91
106	Cotargeting survival signaling pathways in cancer. Journal of Clinical Investigation, 2008, 118, 3003-6.	8.2	106
107	Cotargeting survival signaling pathways in cancer. Journal of Clinical Investigation, 2008, 118, 3513-3513.	8.2	114
108	Phase I Trial of Vorinostat (SAHA) in Combination with Alvocidib (Flavopiridol) in Patients with Relapsed, Refractory or (Selected) Poor Prognosis Acute Leukemia or Refractory Anemia with Excess Blasts-2 (RAEB-2). Blood, 2008, 112, 2986-2986.	1.4	5

#	Article	IF	Citations
109	Mcl-1 Down-regulation Potentiates ABT-737 Lethality by Cooperatively Inducing Bak Activation and Bax Translocation. Cancer Research, 2007, 67, 782-791.	0.9	366
110	Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions. Molecular Cancer Therapeutics, 2007, 6, 692-702.	4.1	66
111	Synergistic Interactions between Vorinostat and Sorafenib in Chronic Myelogenous Leukemia Cells Involve Mcl-1 and p21CIP1 Down-Regulation. Clinical Cancer Research, 2007, 13, 4280-4290.	7.0	63
112	The Kinase Inhibitor Sorafenib Induces Cell Death through a Process Involving Induction of Endoplasmic Reticulum Stress. Molecular and Cellular Biology, 2007, 27, 5499-5513.	2.3	209
113	MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825. Blood, 2007, 109, 4006-4015.	1.4	55
114	MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism. Blood, 2007, 110, 2092-2101.	1.4	43
115	Simultaneous Interruption of Signal Transduction and Cell Cycle Regulatory Pathways: Implications for New Approaches to the Treatment of Childhood Leukemias. Current Drug Targets, 2007, 8, 751-759.	2.1	17
116	Vorinostat. Nature Reviews Drug Discovery, 2007, 6, 21-22.	46.4	381
117	Vorinostat Synergistically Potentiates MK-0457 Lethality in Chronic Myelogenous Leukemia (CML) Cells Sensitive and Resistant to Imatinib Mesylate.. Blood, 2007, 110, 1041-1041.	1.4	3
118	2-Methoxyestradiol-induced apoptosis in human leukemia cells proceeds through a reactive oxygen species and Akt-dependent process. Oncogene, 2005, 24, 3797-3809.	5.9	97
119	Apoptosis Induced by the Kinase Inhibitor BAY 43-9006 in Human Leukemia Cells Involves Down-regulation of Mcl-1 through Inhibition of Translation. Journal of Biological Chemistry, 2005, 280, 35217-35227.	3.4	266
120	Cotreatment with Suberanoylanilide Hydroxamic Acid and 17-Allylamino 17-demethoxygeldanamycin Synergistically Induces Apoptosis in Bcr-Abl+Cells Sensitive and Resistant to STI571 (Imatinib Mesylate) in Association with Down-Regulation of Bcr-Abl, Abrogation of Signal Transducer and Activator of Transcription 5 Activity, and Bax Conformational Change. Molecular Pharmacology, 2005, 67, 1166-1176.	2.3	80
121	Blockade of Histone Deacetylase Inhibitor-Induced RelA/p65 Acetylation and NF-Î²B Activation Potentiates Apoptosis in Leukemia Cells through a Process Mediated by Oxidative Damage, XIAP Downregulation, and c-Jun N-Terminal Kinase 1 Activation. Molecular and Cellular Biology, 2005, 25, 5429-5444.	2.3	237
122	Coadministration of Histone Deacetylase Inhibitors and Perifosine Synergistically Induces Apoptosis in Human Leukemia Cells through Akt and ERK1/2 Inactivation and the Generation of Ceramide and Reactive Oxygen Species. Cancer Research, 2005, 65, 2422-2432.	0.9	195
123	Synergistic Induction of Oxidative Injury and Apoptosis in Human Multiple Myeloma Cells by the Proteasome Inhibitor Bortezomib and Histone Deacetylase Inhibitors. Clinical Cancer Research, 2004, 10, 3839-3852.	7.0	371
124	Contribution of Disruption of the Nuclear Factor-Î²B Pathway to Induction of Apoptosis in Human Leukemia Cells by Histone Deacetylase Inhibitors and Flavopiridol. Molecular Pharmacology, 2004, 66, 956-963.	2.3	54
125	Small molecule inhibitors targeting cyclin-dependent kinases as anticancer agents. Current Oncology Reports, 2004, 6, 123-130.	4.0	53
126	Bile acids induce mitochondrial ROS, which promote activation of receptor tyrosine kinases and signaling pathways in rat hepatocytes. Hepatology, 2004, 40, 961-971.	7.3	115

#	Article	IF	Citations
127	Evidence of a Functional Role for p21WAF1/CIP1Down-Regulation in Synergistic Antileukemic Interactions between the Histone Deacetylase Inhibitor Sodium Butyrate and Flavopiridol. Molecular Pharmacology, 2004, 65, 571-581.	2.3	76
128	The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib. Experimental Cell Research, 2004, 295, 555-566.	2.6	139
129	Activation of MAP Kinase Pathways by TRAIL: Don't Expect the Obvious. Cancer Biology and Therapy, 2004, 3, 302-304.	3.4	0
130	Interruption of the NF-Î¹B pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells. Blood, 2004, 103, 2761-2770.	1.4	104
131	Co-Administration of SAHA and 17-AAG Synergistically Induces Apoptosis in Bcr-Abl+ Cells Sensitive and Resistant to STI-571 in Association with Down-Regulation of Bcr-Abl, Abrogation of STAT5 Activity, and Bax Conformational Change.. Blood, 2004, 104, 1995-1995.	1.4	9
132	Histone deacetylase inhibitors in clinical development. Expert Opinion on Investigational Drugs, 2004, 13, 21-38.	4.1	1
133	Gene profiling and the cyclin-dependent kinase inhibitor flavopiridol: what's in a name?. Molecular Cancer Therapeutics, 2004, 3, 873-5.	4.1	10
134	Inhibition of PI-3 kinase sensitizes human leukemic cells to histone deacetylase inhibitor-mediated apoptosis through p44/42 MAP kinase inactivation and abrogation of p21CIP1/WAF1 induction rather than AKT inhibition. Oncogene, 2003, 22, 6231-6242.	5.9	98
135	Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-Î¹B-dependent process. Oncogene, 2003, 22, 7108-7122.	5.9	136
136	The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy. Drug Resistance Updates, 2003, 6, 15-26.	14.4	54
137	Cyclin-dependent kinase inhibitors. Current Opinion in Pharmacology, 2003, 3, 362-370.	3.5	99
138	An Intact NF-kappaB Pathway is Required for Histone Deacetylase Inhibitor Induced G1 Arrest and Maturation in U937 Human Myeloid Leukemia Cells. Cell Cycle, 2003, 2, 465-470.	2.6	31
139	The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood, 2003, 102, 3765-3774.	1.4	256
140	The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process. Cancer Research, 2003, 63, 1822-33.	0.9	79
141	Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells. Cancer Research, 2003, 63, 2118-26.	0.9	108
142	The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Research, 2003, 63, 3637-45.	0.9	375
143	An intact NF-kappaB pathway is required for histone deacetylase inhibitor-induced G1 arrest and maturation in U937 human myeloid leukemia cells. Cell Cycle, 2003, 2, 467-72.	2.6	20
144	Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Molecular Cancer Therapeutics, 2003, 2, 1273-84.	4.1	181

#	Article	IF	Citations
145	Coadministration of UCN-01 with MEK1/2 Inhibitors Potently Induces Apoptosis in. Cancer Biology and Therapy, 2002, 1, 674-682.	3.4	22
146	Conversion of Drug-Induced Differentiation to Apoptosis by Pharmacologic Cyclin-Dependent Kinase Inhibitors. Cell Cycle, 2002, 1, 383-388.	2.6	15
147	Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6â€“independent mechanism. Blood, 2002, 100, 3333-3343.	1.4	96
148	Roles of Erbb family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival. Frontiers in Bioscience - Landmark, 2002, 7, d376.	3.0	170
149	The Role of Signal Transduction Pathways in Drug and Radiation Resistance. Cancer Treatment and Research, 2002, 112, 89-108.	0.5	7
150	A chicken-or-egg conundrum in apoptosis: which comes first? Ceramide or PKCÎ?. Journal of Clinical Investigation, 2002, 109, 717-719.	8.2	2
151	Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells. Clinical Cancer Research, 2002, 8, 2976-84.	7.0	56
152	The cyclin-dependent kinase inhibitor flavopiridol disrupts sodium butyrate-induced p21WAF1/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells. Molecular Cancer Therapeutics, 2002, 1, 253-66.	4.1	42
153	Hepatitis B virus X protein increases expression of p21Cip-1/WAF1/MDA6 and p27Kip-1 in primary mouse hepatocytes, leading to reduced cell cycle progression. Hepatology, 2001, 34, 906-917.	7.3	59
154	Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activated protein kinase dependent pathways. Oncogene, 2001, 20, 3266-3280.	5.9	121
155	Leucovorin, 5-fluorouracil, and gemcitabine: A phase I study. Investigational New Drugs, 1999, 17, 57-61.	2.6	25
156	Protein Kinase C Targeting in Antineoplastic Treatment Strategies. Investigational New Drugs, 1999, 17, 227-240.	2.6	73
157	Positive and negative regulation of JNK1 by protein kinase C and p42MAP kinasein adult rat hepatocytes. FEBS Letters, 1997, 412, 9-14.	2.8	31
158	Modulation of the expression of Bcl-2 and related proteins in human leukemia cells by protein kinase C activators: relationship to effects on 1-[Î²-D-arabinofuranosyl]cytosine-induced apoptosis. Cell Death and Differentiation, 1997, 4, 294-303.	11.2	6
159	Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature, 1996, 380, 75-79.	27.8	1,789
160	Variable effects of tamoxifen on human hematopoietic progenitor cell growth and sensitivity to doxorubicin. Cancer Chemotherapy and Pharmacology, 1994, 33, 509-514.	2.3	1
161	Effects of bryostatin 1 and rGM-CSF on the metabolism of 1-Î²-d-arabinofuranosylcytosine in human leukaemic myeloblasts. British Journal of Haematology, 1992, 82, 522-528.	2.5	11
162	Effect of pharmacologic manipulation of protein kinase C by phorbol dibutyrate and bryostatin 1 on the clonogenic response of human granulocyte-macrophage progenitors to recombinant GM-CSF. British Journal of Haematology, 1991, 77, 5-15.	2.5	25